All Publications

Data provided by UCSF Profiles, powered by CTSI at UCSF
  1. Groeger M, Matsuo K, Heidary Arash E, Pereira A, Le Guillou D, Pino C, Telles-Silva KA, Maher JJ, Hsiao EC, Willenbring H. Modeling and therapeutic targeting of inflammation-induced hepatic insulin resistance using human iPSC-derived hepatocytes and macrophages. Nat Commun. 2023 07 03; 14(1):3902. View in PubMed
  2. Qi L, Matsuo K, Pereira A, Lee YT, Zhong F, He Y, Zushin PH, Gröger M, Sharma A, Willenbring H, Hsiao EC, Stahl A. Human iPSC-Derived Proinflammatory Macrophages cause Insulin Resistance in an Isogenic White Adipose Tissue Microphysiological System. Small. 2023 08; 19(34):e2203725. View in PubMed
  3. Laemmle A, Häberle J, Willenbring H. Reply. Hepatology. 2022 04; 75(4):1059-1060. View in PubMed
  4. Laemmle A, Poms M, Hsu B, Borsuk M, Rüfenacht V, Robinson J, Sadowski MC, Nuoffer JM, Häberle J, Willenbring H. Aquaporin 9 induction in human iPSC-derived hepatocytes facilitates modeling of ornithine transcarbamylase deficiency. Hepatology. 2022 09; 76(3):646-659. View in PubMed
  5. Lee-Montiel FT, Laemmle A, Charwat V, Dumont L, Lee CS, Huebsch N, Okochi H, Hancock MJ, Siemons B, Boggess SC, Goswami I, Miller EW, Willenbring H, Healy KE. Integrated Isogenic Human Induced Pluripotent Stem Cell-Based Liver and Heart Microphysiological Systems Predict Unsafe Drug-Drug Interaction. Front Pharmacol. 2021; 12:667010. View in PubMed
  6. Duwaerts CC, Le Guillou D, Her CL, Phillips NJ, Willenbring H, Mattis AN, Maher JJ. Induced Pluripotent Stem Cell-derived Hepatocytes From Patients With Nonalcoholic Fatty Liver Disease Display a Disease-specific Gene Expression Profile. Gastroenterology. 2021 06; 160(7):2591-2594.e6. View in PubMed
  7. Kurial SNT, Willenbring H. Emerging cell therapy for biliary diseases. Science. 2021 02 19; 371(6531):786-787. View in PubMed
  8. Kurial SNT, Willenbring H. Transcriptomic Traces of Adult Human Liver Progenitor Cells. Hepatology. 2020 04; 71(4):1504-1507. View in PubMed
  9. Chen F, Jimenez RJ, Sharma K, Luu HY, Hsu BY, Ravindranathan A, Stohr BA, Willenbring H. Broad Distribution of Hepatocyte Proliferation in Liver Homeostasis and Regeneration. Cell Stem Cell. 2020 01 02; 26(1):27-33.e4. View in PubMed
  10. Huck I, Gunewardena S, Espanol-Suner R, Willenbring H, Apte U. Hepatocyte Nuclear Factor 4 Alpha Activation Is Essential for Termination of Liver Regeneration in Mice. Hepatology. 2019 08; 70(2):666-681. View in PubMed
  11. Schaub JR, Huppert KA, Kurial SNT, Hsu BY, Cast AE, Donnelly B, Karns RA, Chen F, Rezvani M, Luu HY, Mattis AN, Rougemont AL, Rosenthal P, Huppert SS, Willenbring H. De novo formation of the biliary system by TGFβ-mediated hepatocyte transdifferentiation. Nature. 2018 05; 557(7704):247-251. View in PubMed
  12. Ian Huck, Sumedha Gunewardena, Regina Espanol-Suner, Holger Willenbring, Udayan Apte. Hepatocyte Nuclear Factor 4 alpha (HNF4a) Activation is Essential for Termination of Liver Regeneration. bioRxiv. 2018 Apr 20; 304808. View in PubMed
  13. Ian Huck, Sumedha Gunewardena, Regina Espanol-Suner, Holger Willenbring, Udayan Apte. Hepatocyte Nuclear Factor 4 alpha (HNF4a) Activation is Essential for Termination of Liver Regeneration. . 2018 Apr 20; 304808. View in PubMed
  14. Holger Willenbring. Postnatal Organogenesis by Transdifferentiation. The FASEB Journal. 2018 Apr 1; 32:240.3-240.3. View in PubMed
  15. Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol. 2016 Dec; 7(6):819-827. View in PubMed
  16. Rezvani M, Español-Suñer R, Malato Y, Dumont L, Grimm AA, Kienle E, Bindman JG, Wiedtke E, Hsu BY, Naqvi SJ, Schwabe RF, Corvera CU, Grimm D, Willenbring H. In Vivo Hepatic Reprogramming of Myofibroblasts with AAV Vectors as a Therapeutic Strategy for Liver Fibrosis. Cell Stem Cell. 2016 06 02; 18(6):809-816. View in PubMed
  17. Rezvani M, Grimm AA, Willenbring H. Assessing the therapeutic potential of lab-made hepatocytes. Hepatology. 2016 07; 64(1):287-94. View in PubMed
  18. Desai SS, Tung JC, Zhou VX, Grenert JP, Malato Y, Rezvani M, Español-Suñer R, Willenbring H, Weaver VM, Chang TT. Physiological ranges of matrix rigidity modulate primary mouse hepatocyte function in part through hepatocyte nuclear factor 4 alpha. Hepatology. 2016 07; 64(1):261-75. View in PubMed
  19. Mattis AN, Song G, Hitchner K, Kim RY, Lee AY, Sharma AD, Malato Y, McManus MT, Esau CC, Koller E, Koliwad S, Lim LP, Maher JJ, Raffai RL, Willenbring H. A screen in mice uncovers repression of lipoprotein lipase by microRNA-29a as a mechanism for lipid distribution away from the liver. Hepatology. 2015 Jan; 61(1):141-52. View in PubMed
  20. Hentzschel F, Hammerschmidt-Kamper C, Börner K, Heiss K, Knapp B, Sattler JM, Kaderali L, Castoldi M, Bindman JG, Malato Y, Willenbring H, Mueller AK, Grimm D. AAV8-mediated in vivo overexpression of miR-155 enhances the protective capacity of genetically attenuated malarial parasites. Mol Ther. 2014 12; 22(12):2130-2141. View in PubMed
  21. Johanna R. Schaub, Yann Malato, Coralie Gormond, Holger Willenbring. Evidence against a Stem Cell Origin of New Hepatocytes in a Common Mouse Model of Chronic Liver Injury. Cell Reports. 2014 Sep 1; 8(5):1607. View in PubMed
  22. Johanna R. Schaub, Yann Malato, Coralie Gormond, Holger Willenbring. Evidence against a Stem Cell Origin of New Hepatocytes in a Common Mouse Model of Chronic Liver Injury. . 2014 Sep 1; 8(5):1607. View in PubMed
  23. Schaub JR, Malato Y, Gormond C, Willenbring H. Evidence against a stem cell origin of new hepatocytes in a common mouse model of chronic liver injury. Cell Rep. 2014 Aug 21; 8(4):933-9. View in PubMed
  24. Lee RH, Roll G, Nguyen V, Willenbring H, Tang Q, Kang SM, Stock PG. Failure to achieve normal metabolic response in non-obese diabetic mice and streptozotocin-induced diabetic mice after transplantation of primary murine hepatocytes electroporated with the human proinsulin gene (p3MTChins). Transplant Proc. 2014 Jul-Aug; 46(6):2002-6. View in PubMed
  25. Espejel S, Eckardt S, Harbell J, Roll GR, McLaughlin KJ, Willenbring H. Brief report: Parthenogenetic embryonic stem cells are an effective cell source for therapeutic liver repopulation. Stem Cells. 2014 Jul; 32(7):1983-8. View in PubMed
  26. Ng R, Wu H, Xiao H, Chen X, Willenbring H, Steer CJ, Song G. Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology. 2014 Aug; 60(2):554-64. View in PubMed
  27. Zhu S, Rezvani M, Harbell J, Mattis AN, Wolfe AR, Benet LZ, Willenbring H, Ding S. Mouse liver repopulation with hepatocytes generated from human fibroblasts. Nature. 2014 Apr 03; 508(7494):93-7. View in PubMed
  28. Mitchell C, Willenbring H. Addendum: A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nat Protoc. 2014; 9(6). View in PubMed
  29. Mathur A, Loskill P, Hong S, Lee J, Marcus SG, Dumont L, Conklin BR, Willenbring H, Lee LP, Healy KE. Human induced pluripotent stem cell-based microphysiological tissue models of myocardium and liver for drug development. Stem Cell Res Ther. 2013; 4 Suppl 1:S14. View in PubMed
  30. Lim L, Balakrishnan A, Huskey N, Jones KD, Jodari M, Ng R, Song G, Riordan J, Anderton B, Cheung ST, Willenbring H, Dupuy A, Chen X, Brown D, Chang AN, Goga A. MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology. 2014 Jan; 59(1):202-15. View in PubMed
  31. Willenbring H, Soto-Gutierrez A. Transplantable liver organoids made from only three ingredients. Cell Stem Cell. 2013 Aug 01; 13(2):139-40. View in PubMed
  32. Ma X, Duan Y, Tschudy-Seney B, Roll G, Behbahan IS, Ahuja TP, Tolstikov V, Wang C, McGee J, Khoobyari S, Nolta JA, Willenbring H, Zern MA. Highly efficient differentiation of functional hepatocytes from human induced pluripotent stem cells. Stem Cells Transl Med. 2013 Jun; 2(6):409-19. View in PubMed
  33. Willenbring H, Grompe M. A therapy for liver failure found in the JNK yard. Cell. 2013 Apr 11; 153(2):283-4. View in PubMed
  34. M Evert, B Fan, Y Malato, S Ribback, F Dombrowski, H Willenbring, X Chen, DF Calvisi. Akt/Notch activation drives rapid cholangiocarcinoma development originating from mature hepatocytes in the mouse. . 2013 Jan 11; 51(01). View in PubMed
  35. M Evert, B Fan, Y Malato, S Ribback, F Dombrowski, H Willenbring, X Chen, DF Calvisi. Akt/Notch activation drives rapid cholangiocarcinoma development originating from mature hepatocytes in the mouse. Zeitschrift für Gastroenterologie. 2013 Jan 11; 51(01). View in PubMed
  36. Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, Gores GJ, Dombrowski F, Evert M, Chen X, Willenbring H. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012 Aug; 122(8):2911-5. View in PubMed
  37. Mattis AN, Willenbring H. A ZFN/piggyBac step closer to autologous liver cell therapy. Hepatology. 2012 Jun; 55(6):2033-5. View in PubMed
  38. Ng R, Song G, Roll GR, Frandsen NM, Willenbring H. A microRNA-21 surge facilitates rapid cyclin D1 translation and cell cycle progression in mouse liver regeneration. J Clin Invest. 2012 Mar; 122(3):1097-108. View in PubMed
  39. Rountree CB, Mishra L, Willenbring H. Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology. 2012 Jan; 55(1):298-306. View in PubMed
  40. Malato Y, Naqvi S, Schürmann N, Ng R, Wang B, Zape J, Kay MA, Grimm D, Willenbring H. Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest. 2011 Dec; 121(12):4850-60. View in PubMed
  41. Willenbring H. A simple code for installing hepatocyte function. Cell Stem Cell. 2011 Aug 05; 9(2):89-91. View in PubMed
  42. Eckardt S, McLaughlin KJ, Willenbring H. Mouse chimeras as a system to investigate development, cell and tissue function, disease mechanisms and organ regeneration. Cell Cycle. 2011 Jul 01; 10(13):2091-9. View in PubMed
  43. D'Alessio JA, Ng R, Willenbring H, Tjian R. Core promoter recognition complex changes accompany liver development. Proc Natl Acad Sci U S A. 2011 Mar 08; 108(10):3906-11. View in PubMed
  44. Malato Y, Willenbring H. The MAP3K TAK1: a chock block to liver cancer formation. Hepatology. 2010 Oct; 52(4):1506-9. View in PubMed
  45. Espejel S, Roll GR, McLaughlin KJ, Lee AY, Zhang JY, Laird DJ, Okita K, Yamanaka S, Willenbring H. Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice. J Clin Invest. 2010 Sep; 120(9):3120-6. View in PubMed
  46. Roll GR, Willenbring H. Transplanted nonviable human hepatocytes produce appreciable serum albumin levels in mice. Stem Cell Res. 2010 Nov; 5(3):267-70. View in PubMed
  47. Saunders LR, Sharma AD, Tawney J, Nakagawa M, Okita K, Yamanaka S, Willenbring H, Verdin E. miRNAs regulate SIRT1 expression during mouse embryonic stem cell differentiation and in adult mouse tissues. Aging (Albany NY). 2010 Jul; 2(7):415-31. View in PubMed
  48. Erker L, Azuma H, Lee AY, Guo C, Orloff S, Eaton L, Benedetti E, Jensen B, Finegold M, Willenbring H, Grompe M. Therapeutic liver reconstitution with murine cells isolated long after death. Gastroenterology. 2010 Sep; 139(3):1019-29. View in PubMed
  49. Song G, Sharma AD, Roll GR, Ng R, Lee AY, Blelloch RH, Frandsen NM, Willenbring H. MicroRNAs control hepatocyte proliferation during liver regeneration. Hepatology. 2010 May; 51(5):1735-43. View in PubMed
  50. Willenbring H, Sharma AD, Vogel A, Lee AY, Rothfuss A, Wang Z, Finegold M, Grompe M. Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. Cancer Cell. 2008 Jul 08; 14(1):59-67. View in PubMed
  51. ?? ???, J Kahn, H Willenbring, ?? ??, ?? ??, ?? ??. ????????in vitro???. . 2008 Mar 1; 717-717. View in PubMed
  52. ?? ???, J Kahn, H Willenbring, ?? ??, ?? ??, ?? ??. ????????in vitro???. . 2008 Mar 1; 717-717. View in PubMed
  53. Mitchell C, Willenbring H. A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nat Protoc. 2008; 3(7):1167-70. View in PubMed
  54. Ramalho-Santos M, Willenbring H. On the origin of the term "stem cell". Cell Stem Cell. 2007 Jun 07; 1(1):35-38. View in PubMed
  55. Bailey AS, Willenbring H, Jiang S, Anderson DA, Schroeder DA, Wong MH, Grompe M, Fleming WH. Myeloid lineage progenitors give rise to vascular endothelium. Proc Natl Acad Sci U S A. 2006 Aug 29; 103(35):13156-61. View in PubMed
  56. Rizvi AZ, Swain JR, Davies PS, Bailey AS, Decker AD, Willenbring H, Grompe M, Fleming WH, Wong MH. Bone marrow-derived cells fuse with normal and transformed intestinal stem cells. Proc Natl Acad Sci U S A. 2006 Apr 18; 103(16):6321-5. View in PubMed
  57. Vogel A, Aslan JE, Willenbring H, Klein C, Finegold M, Mount H, Thomas G, Grompe M. Sustained phosphorylation of Bid is a marker for resistance to Fas-induced apoptosis during chronic liver diseases. Gastroenterology. 2006 Jan; 130(1):104-19. View in PubMed
  58. Alexis S. Bailey, Holger Willenbring, Shuguang Jiang, David A. Schroeder, Daniel A. Anderson, Markus Grompe, Melissa H. Wong, William H. Fleming. Myeloid Lineage-Restricted Progenitors Contribute to Vascular Endothelium. Blood. 2005 Nov 16; 106(11):2267-2267. View in PubMed
  59. Held PK, Al-Dhalimy M, Willenbring H, Akkari Y, Jiang S, Torimaru Y, Olson S, Fleming WH, Finegold M, Grompe M. In vivo genetic selection of renal proximal tubules. Mol Ther. 2006 Jan; 13(1):49-58. View in PubMed
  60. Willenbring H. Therapeutic cell fusion. Br J Surg. 2005 Aug; 92(8):923-4. View in PubMed
  61. Willenbring H, Grompe M. Delineating the hepatocyte's hematopoietic fusion partner. Cell Cycle. 2004 Dec; 3(12):1489-91. View in PubMed
  62. Willenbring H, Bailey AS, Foster M, Akkari Y, Dorrell C, Olson S, Finegold M, Fleming WH, Grompe M. Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. Nat Med. 2004 Jul; 10(7):744-8. View in PubMed
  63. Willenbring H, Grompe M. Embryonic versus adult stem cell pluripotency: in liver only fusion matters. J Assist Reprod Genet. 2003 Oct; 20(10):393-4. View in PubMed
  64. Wang X, Willenbring H, Akkari Y, Torimaru Y, Foster M, Al-Dhalimy M, Lagasse E, Finegold M, Olson S, Grompe M. Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature. 2003 Apr 24; 422(6934):897-901. View in PubMed
  65. Linnebank M, Tschiedel E, Häberle J, Linnebank A, Willenbring H, Kleijer WJ, Koch HG. Argininosuccinate lyase (ASL) deficiency: mutation analysis in 27 patients and a completed structure of the human ASL gene. Hum Genet. 2002 Oct; 111(4-5):350-9. View in PubMed
  66. Homberger A, Linnebank M, Winter C, Willenbring H, Marquardt T, Harms E, Koch HG. Genomic structure and transcript variants of the human methylenetetrahydrofolate reductase gene. Eur J Hum Genet. 2000 Sep; 8(9):725-9. View in PubMed
  67. Poremba C, Willenbring H, Hero B, Christiansen H, Schäfer KL, Brinkschmidt C, Jürgens H, Böcker W, Dockhorn-Dworniczak B. Telomerase activity distinguishes between neuroblastomas with good and poor prognosis. Ann Oncol. 1999 Jun; 10(6):715-21. View in PubMed
  68. Poremba C, Böcker W, Willenbring H, Schäfer KL, Otterbach F, Bürger H, Diallo R, Dockhorn-Dworniczak B. Telomerase activity in human proliferative breast lesions. Int J Oncol. 1998 Mar; 12(3):641-8. View in PubMed
  69. Hiort O, Sinnecker GH, Willenbring H, Lehners A, Zöllner A, Struve D. Nonisotopic single strand conformation analysis of the 5 alpha-reductase type 2 gene for the diagnosis of 5 alpha-reductase deficiency. J Clin Endocrinol Metab. 1996 Sep; 81(9):3415-8. View in PubMed
  70. Hiort O, Willenbring H, Albers N, Hecker W, Engert J, Dibbelt L, Sinnecker GH. Molecular genetic analysis and human chorionic gonadotropin stimulation tests in the diagnosis of prepubertal patients with partial 5 alpha-reductase deficiency. Eur J Pediatr. 1996 Jun; 155(6):445-51. View in PubMed